Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) CEO Jason Eric Evans sold 26,520 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $25.65, for a total transaction of $680,238.00. Following the completion of the sale, the chief executive officer now directly owns 560,698 shares in the company, valued at $14,381,903.70. This trade represents a 4.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Surgery Partners Stock Performance
Shares of SGRY stock opened at $25.35 on Thursday. The company has a market capitalization of $3.22 billion, a P/E ratio of -52.81, a P/E/G ratio of 17.77 and a beta of 2.60. Surgery Partners, Inc. has a 12-month low of $19.50 and a 12-month high of $35.29. The business’s 50 day moving average is $21.99 and its two-hundred day moving average is $26.84. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). The company had revenue of $770.40 million during the quarter, compared to analyst estimates of $768.99 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Surgery Partners’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 EPS. Analysts expect that Surgery Partners, Inc. will post 0.71 EPS for the current fiscal year.
Institutional Trading of Surgery Partners
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a report on Tuesday, December 3rd. Royal Bank of Canada lowered their target price on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Bank of America started coverage on Surgery Partners in a report on Monday, December 16th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Macquarie reissued an “outperform” rating and issued a $34.00 price target on shares of Surgery Partners in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Surgery Partners has an average rating of “Moderate Buy” and a consensus price target of $36.56.
Check Out Our Latest Stock Analysis on Surgery Partners
About Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Recommended Stories
- Five stocks we like better than Surgery Partners
- How to buy stock: A step-by-step guide for beginners
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Inflation Persists, But So Do Stock Opportunities: Rally On
- How to Calculate Return on Investment (ROI)
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.